

Sa Australian Shareholders' Association

Australian Shareholders' Association Limited ABN 40 000 625 669 Suite 11, Level 22 227 Elizabeth Street, Sydney NSW 2000 PO Box A398, Sydney South NSW 1235 t (02) 9252 4244 | f (02) 9071 9877 e share@asa.asn.au

Company/ASX Code	Codan Limited/CDA	
AGM date	28 th October	
Time and location	11am Virtual Meeting	
Registry	Computershare	
Webcast	https://web.lumiagm.com ID 384-150-475	
Poll or show of hands	Vote online	
Monitor	Brad Martin & Malcolm Keynes	
Pre AGM Meeting?	No meeting: questions answered via email.	

General Business 2020 Financial Statements

No vote required.

Ordinary Business

Item 1	Adoption of Remuneration Report
ASA Vote	For

With highest sales in the company's history of \$348 million, record statutory net profit after tax of \$64 million an increase of 40%, annual dividend of 18.5 cents fully franked on earnings per share of 35.5 cents which is an increase of 39% and a balance sheet of \$92.8 net cash in what has been a challenging year for the world.

Item 2	Re-election of Director – Mr Graham Barclay		
ASA Vote	For		

Mr Barclay has been appointed to the board in 2015 and has more than 30 years of international business experience.

Special Business

Item 3	Approval of the grant of Performance Rights to Mr Donald McGurk
ASA Vote	For

As it is based on a maximum of 50% of fixed income and has a zero entitlement at threshold, LTI incentive is modest. The threshold is testing, as is the maximum. We would prefer a four year timeline.

Another record year despite trying conditions

ASA focus issues

Directors and Boards.

While there have been no board changes, diversity is lower that we like to see, the company has performed well.

Remuneration, culture and performance

Remuleration, culture and performance					
CEO rem. Framework	Target* \$000	% of total	Max. Opportunity \$000	% of total	
Fixed Remuneration	597	50%	597	40%	
STI	298	25%	597	40%	
LTI	298	25%	298	20%	
Total	1,194	100%	1,492	100%	

STI is paid in cash.

LTI is issue of performance rights that convert into shares. We would prefer the vesting period to be four years over the current three years.

Culture – 10% of sales is used for R & D and 1% on Staff Development. Staff satisfaction is high.

Performance					
(As at FYE)	2020	2019	2018	2017	2016
NPAT (\$m)	64	45.7	41.6	43.5	15.5
UPAT (\$m)	64	45.7	39.8	44.7	21.1
Share price (\$)	7.09	3.48	2.98	2.34	1.18
Dividend (cents)	18.5	9	8.5	7	6
TSR (%)	109	21	33	109	10
EPS (cents)	35.3	25.5	22.1	24.9	11.9
CEO total remuneration,	1.45	1.22	1.15	1.42	0.96
Actual (\$m)					

Risk management

Standing up for shareholders

Codan has a strong balance sheet with no debt and has dealt effectively with Covid19 and is continually developing policies to meet conditions and market expectations.

Shareholder participation

No capital raisings during the year and Codan has kept the market well informed.

ASA Disclaimer

This document has been prepared by the Australian Shareholders Association Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not constitute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommendations of a particular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- makes any representations, warranties or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or information contained in this document; or
- shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any
 statements or information contained in, or omissions from this document; nor for any person's acts or omissions undertaken
 or made in reliance of any such statements, information or omissions.

This document may contain forward looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cautioned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obligation to disseminate any updates or revisions to any such statements to reflect changed expectations or circumstances.